Search results for " evaluation"

showing 10 items of 1458 documents

Predicting drug-induced cholestasis: preclinical models.

2018

In almost 50% of patients with drug-induced liver injury (DILI), the bile flow from the liver to the duodenum is impaired, a condition known as cholestasis. However, this toxic response only appears in a small percentage of the treated patients (idiosyncrasy). Prediction of drug-induced cholestasis (DIC) is challenging and emerges as a safety issue that requires attention by professionals in clinical practice, regulatory authorities, pharmaceutical companies, and research institutions. Area covered: The current synopsis focuses on the state-of-the-art in preclinical models for cholestatic DILI prediction. These models differ in their goal, complexity, availability, and applicability, and ca…

0301 basic medicineIdiosyncrasymedicine.drug_classDrug Evaluation PreclinicalIn Vitro TechniquesToxicologyBioinformaticsModels BiologicalBile flow03 medical and health sciencesCholestasismedicineAnimalsBileHumansDrug induced cholestasisPharmacologyLiver injuryCholestasisBile acidbusiness.industryReproducibility of ResultsGeneral Medicinemedicine.disease030104 developmental biologymedicine.anatomical_structureHepatocyteDuodenumHepatocytesChemical and Drug Induced Liver InjurybusinessExpert opinion on drug metabolismtoxicology
researchProduct

Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes

2018

Modification of SMN2 exon 7 (E7) splicing is a validated therapeutic strategy against spinal muscular atrophy (SMA). However, a target-based approach to identify small-molecule E7 splicing modifiers has not been attempted, which could reveal novel therapies with improved mechanistic insight. Here, we chose as a target the stem-loop RNA structure TSL2, which overlaps with the 5′ splicing site of E7. A small-molecule TSL2-binding compound, homocarbonyltopsentin (PK4C9), was identified that increases E7 splicing to therapeutic levels and rescues downstream molecular alterations in SMA cells. High-resolution NMR combined with molecular modelling revealed that PK4C9 binds to pentaloop conformati…

0301 basic medicineIndolesCOMPOUND LIBRARIESDrug Evaluation PreclinicalGeneral Physics and AstronomyBiotecnologiaAnimals Genetically ModifiedExonMolecular Targeted TherapyRegulatory Elements Transcriptionallcsh:ScienceHUMAN-DISEASE GENESBIOACTIVE SMALL MOLECULESMultidisciplinaryChemistryDrug discovery[CHIM.ORGA]Chemical Sciences/Organic chemistryQImidazolesMUTATION PATTERNExonsSMA*3. Good healthCell biologySurvival of Motor Neuron 2 ProteinPhenotypeCribratgeRNA splicingNUCLEOTIDE STRUCTUREDrosophilaMESSENGER-RNACOMPUTATIONAL TOOLSMedical screeningMYOTONIC-DYSTROPHYScienceMuscular atrophyArticleGeneral Biochemistry Genetics and Molecular BiologyGenètica molecularMuscular Atrophy Spinal03 medical and health sciencesddc:570SPLICING MODIFIERSmedicineAnimalsHumansHIV-1 TARRNA MessengerAtròfia muscularMessenger RNAAlternative splicingRNAGeneral ChemistrySpinal muscular atrophymedicine.diseaseAlternative Splicing030104 developmental biologyRNAlcsh:QRNA Splice SitesHeLa CellsNature Communications
researchProduct

CD1A-positive cells and HSP60 (HSPD1) levels in keratoacanthoma and squamous cell carcinoma.

2015

CD1a is involved in presentation to the immune system of lipid antigen derived from tumor cells with subsequent T cell activation. Hsp60 is a molecular chaperone implicated in carcinogenesis by, for instance, modulating the immune reaction against the tumor. We have previously postulated a synergism between CD1a and Hsp60 as a key factor in the activation of an effective antitumor immune response in squamous epithelia. Keratoacantomas (KAs) are benign tumors that however can transform into squamous cell carcinomas (SCCs), but the reasons for this malignization are unknown. In a previous study, we found that CD1a-positive cells are significantly more numerous in KA than in SCC. In this study…

0301 basic medicineKeratoacanthomaCellmedicine.disease_causeBiochemistryAntigens CD10302 clinical medicineSquamous cell carcinomaAged 80 and overintegumentary systemPrognostic evaluationMiddle AgedHsp60ImmunohistochemistryKeratoacanthomamedicine.anatomical_structure030220 oncology & carcinogenesisCarcinoma Squamous CellImmunohistochemistryHSP60AdultT cellDifferential diagnosichemical and pharmacologic phenomenaCD1aBiologySettore MED/08 - Anatomia PatologicaDiagnosis DifferentialMitochondrial Proteins03 medical and health sciencesYoung AdultKeratoacantomaImmune systemmedicineBiomarkers TumorHumansAgedRetrospective StudiesOriginal PaperSettore BIO/16 - Anatomia UmanaCD1a; Differential diagnosis; Hsp60; Immunohistochemistry; Keratoacantoma; Prognostic evaluation; Squamous cell carcinoma; Treatment; Biochemistry; Cell BiologyfungiCell BiologyChaperonin 60medicine.diseaseTreatmentstomatognathic diseases030104 developmental biologyCancer researchDifferential diagnosisCarcinogenesisCell stresschaperones
researchProduct

Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects.

2018

Herbal extracts represent an ample source of natural compounds, with potential to be used in improving human health. There is a growing interest in using natural extracts as possible new treatment strategies for inflammatory diseases. We therefore aimed at identifying herbal extracts that affect inflammatory signaling pathways through toll-like receptors (TLRs), TLR2 and TLR4. Ninety-nine ethanolic extracts were screened in THP-1 monocytes and HeLa-TLR4 transfected reporter cells for their effects on stimulated TLR2 and TLR4 signaling pathways. The 28 identified anti-inflammatory extracts were tested in comparative assays of stimulated HEK-TLR2 and HEK-TLR4 transfected reporter cells to dif…

0301 basic medicineLeavesHumulus lupulusTHP-1 CellsPhysiologymedicine.medical_treatmentAnti-Inflammatory AgentsDrug Evaluation Preclinicallcsh:MedicinePlant SciencePharmacologyPlant RootsImmune ReceptorsBiochemistryMonocytesWhite Blood CellsCell SignalingAnimal CellsImmune PhysiologyMedicine and Health SciencesMembrane Receptor Signalinglcsh:ScienceToll-like ReceptorsFlowering PlantsInnate Immune SystemMultidisciplinaryImmune System ProteinsbiologyOrganic CompoundsPlant AnatomyEukaryotaPlantsImmune Receptor SignalingChemistryCytokinevisual_artPhysical Sciencesvisual_art.visual_art_mediumPlant BarkCytokinesBarkSignal transductionCellular TypesResearch ArticleSignal Transductionmedicine.drug_classImmune CellsImmunologyTransfectionAnti-inflammatory03 medical and health sciencesmedicineHumansBlood CellsEthanolPlant ExtractsMacrophagesCinnamomum verumlcsh:ROrganic ChemistryOrganismsChemical CompoundsBiology and Life SciencesProteinsCell BiologyMolecular Developmentbiology.organism_classificationToll-Like Receptor 2Plant LeavesToll-Like Receptor 4TLR2030104 developmental biologyHEK293 CellsGene Expression RegulationCell cultureAlcoholsImmune Systemlcsh:QHeLa CellsDevelopmental BiologyPloS one
researchProduct

VEGF-R2/Caveolin-1 Pathway of Undifferentiated ARPE-19 Retina Cells: A Potential Target as Anti-VEGF-A Therapy in Wet AMD by Resvega, an Omega-3/Poly…

2021

Age-related macular degeneration (AMD) is one of the main causes of deterioration in vision in adults aged 55 and older. In spite of therapies, the progression of the disease is often observed without reverse vision quality. In the present study, we explored whether, in undifferentiated ARPE-19 retinal cells, a disruption of the VEGF receptors (VEGF-R)/caveolin-1 (Cav-1)/protein kinases pathway could be a target for counteracting VEGF secretion. We highlight that Resvega®, a combination of omega-3 fatty acids with an antioxidant, resveratrol, inhibits VEGF-A secretion in vitro by disrupting the dissociation of the VEGF-R2/Cav-1 complex into rafts and subsequently preventing MAPK activation.…

0301 basic medicineMAP Kinase Signaling SystemAngiogenesisQH301-705.5Caveolin 1Drug Evaluation PreclinicalresveratrolResveratrolAMDRetinaArticleCatalysisCell LineVEGF-receptorInorganic ChemistryMacular Degeneration03 medical and health scienceschemistry.chemical_compoundangiogenesis0302 clinical medicinemedicineHumansSecretionPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyRetinaomega-3 fatty acidsKinaseOrganic Chemistryocular diseasesRetinalGeneral MedicineVascular Endothelial Growth Factor Receptor-2VEGFIn vitroComputer Science ApplicationsTranscription Factor AP-1Chemistry030104 developmental biologymedicine.anatomical_structurechemistry030220 oncology & carcinogenesisCaveolin 1Cancer researchInternational Journal of Molecular Sciences
researchProduct

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option

2017

Abstract: Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer. Recent studies evaluated the genomic landscape of BTCs and…

0301 basic medicineMAPK/ERK pathwayVascular Endothelial Growth Factor AAngiogenesisDrug Evaluation PreclinicalTyrosine kinase inhibitorAngiogenesis InhibitorsReviewFibroblast growth factorCatalysiMetastasisAntineoplastic Agentlcsh:Chemistrychemistry.chemical_compoundangiogenesis0302 clinical medicinetyrosine kinase inhibitorsMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyClinical Trials as TopicMonoclonal antibodieNeovascularization Pathologicvascular endothelial growth factorComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineComputer Science ApplicationsVascular endothelial growth factorGene Expression Regulation NeoplasticAngiogenesiChemistryBiliary Tract NeoplasmsTreatment OutcomeBiliary Tract Neoplasm030220 oncology & carcinogenesismonoclonal antibodiesTyrosine kinaseAngiogenesis InhibitorHumanSignal TransductionProtein Kinase InhibitorAntineoplastic Agentsbiliary tract cancersBiologyModels BiologicalAngiogenesis; Biliary tract cancers; Monoclonal antibodies; Tyrosine kinase inhibitors; Vascular endothelial growth factor; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Clinical Trials as Topic; Drug Evaluation Preclinical; Gene Expression Regulation Neoplastic; Genetic Variation; Humans; Models Biological; Neovascularization Pathologic; Protein Kinase Inhibitors; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A; Molecular Targeted Therapy; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryCatalysisInorganic Chemistry03 medical and health sciencesIn vivomedicineAnimalsHumansPhysical and Theoretical ChemistryGallbladder cancerMolecular BiologyProtein Kinase InhibitorsBiologyAnimalOrganic ChemistryGenetic Variationmedicine.disease030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Immunologyangiogenesis; biliary tract cancers; monoclonal antibodies; tyrosine kinase inhibitors; vascular endothelial growth factorCancer researchBiliary tract cancerInternational Journal of Molecular Sciences
researchProduct

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

2018

Introduction IMAB362 (Zolbetuximab) is a chimeric monoclonal antibody that binds to Claudin-18.2, a target antigen specific to cancer cells. In vitro, IMAB362 mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity; thus, IMAB362 may serve as a potent, targeted immunotherapeutic agent. Methods This first-in-human phase I study enroled adult patients (N = 15) with advanced gastric or gastro-oesophageal junction cancer into five sequential single dose-escalation cohorts (33, 100, 300, 600, and 1000 mg/m2) following a 3 + 3 design. Safety/tolerability, including determination of maximum tolerated dose and recommended phase II dose, were the pr…

0301 basic medicineMaleCancer Researchmedicine.medical_specialtyTime FactorsEsophageal NeoplasmsMaximum Tolerated Dosemedicine.medical_treatmentMedizinGastroenterologyAntibodies Monoclonal/administration & dosage03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalPharmacokineticsAntineoplastic Agents Immunological/administration & dosageStomach NeoplasmsInternal medicineGermanymedicineHumansDrug Dosage CalculationsAdverse effectInfusions IntravenousAgedbusiness.industryCancerAntibodies MonoclonalEsophagogastric Junction/drug effectsImmunotherapyMiddle Agedmedicine.diseaseLatviaddc:030104 developmental biologyTreatment OutcomeOncologyTolerabilityResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisToxicityDisease ProgressionFemaleStomach Neoplasms/drug therapyEsophagogastric JunctionEsophageal Neoplasms/drug therapybusinessProgressive disease
researchProduct

Home-Delivered Meals: Characterization of Food Intake in Elderly Beneficiaries

2021

Objective. In this study, we focus on elderly people (≥70 years old) benefiting from a home delivery meal service as part of a social welfare program. We aimed to: (i) assess the gap between the recommended and actual nutritional intake in this population and (ii) study the relationship between the intake of nutrients and the variables characterizing the participants’ health and nutritional status. Design. A dietary survey (24-hour record) was conducted during a home interview, with 64 people receiving a home delivery meal service (75% women

0301 basic medicineMaleFood intakeProtein–energy malnutritionPopulationOverweightDiet SurveysArticleprotein-energy malnutritionhome care servicesInterviews as Topic03 medical and health sciencesEating0302 clinical medicineHome delivered mealsEnvironmental healthmedicineHumansDietary surveyTX341-641nutritional intake030212 general & internal medicineeducationGeriatric Assessmentolder adultsAged2. Zero hungerAged 80 and overMealeducation.field_of_study030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryNutrition. Foods and food supply[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyFood Servicesmedicine.disease3. Good healthMalnutritionmeals-on-wheelsFemalemedicine.symptombusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionFood ScienceProgram EvaluationNutrients
researchProduct

Blood zinc levels and cognitive and functional evaluation in non-demented older patients.

2018

A complete battery of geriatric and psychometric tests was used to determine whether plasma-borne zinc (Zn), a key ion in neuroplasticity, can be associated with the severity of functional, psychological and cognitive impairment in non-demented older individuals. There was a significant positive correlation between plasma Zn levels and the concentration subcategory measured with the Mini-Mental State Examination (MMSE) test (p  0.001), but not the total MMSE score, and the levels were significantly reduced in polymedicated patients (defined as concurrent administration of5 drugs). No correlations were found between plasma Zn levels and depressive symptoms measured with the Yesavage scale fo…

0301 basic medicineMalemedicine.medical_specialtyAgingActivities of daily livingBarthel indexBiochemistrySeverity of Illness Index03 medical and health sciences0302 clinical medicineEndocrinologyCognitionOlder patientsInternal medicineActivities of Daily LivingGeneticsMedicineHumansCognitive DysfunctionMolecular BiologyGeriatric AssessmentDepression (differential diagnoses)AgedAged 80 and overPsychiatric Status Rating ScalesFunctional evaluationMini–Mental State Examinationmedicine.diagnostic_testbusiness.industryDepressionCognitionCell BiologyMiddle AgedPoor sleepZinc030104 developmental biologySpainFemalebusiness030217 neurology & neurosurgeryExperimental gerontology
researchProduct

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

2020

[Background] Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib shows higher activity than in previous studies with chemotherapy. We designed a trial to test pazopanib activity in two different cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was previously published, and the typical cohort, which is presented here.

0301 basic medicineMalemedicine.medical_specialtyIndazolesPazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointHumansProspective StudiesNeoplasm MetastasisProspective cohort studySurvival rateProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedSulfonamidesPerformance statusbusiness.industryMiddle Agedmedicine.diseasePrognosisClinical trialSurvival Rate030104 developmental biologyPyrimidinesOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisSolitary Fibrous TumorsFemalebusinessProgressive diseasemedicine.drugFollow-Up Studies
researchProduct